These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 8179225

  • 1. Management options: SCIDS with adenosine deaminase deficiency.
    Hilman BC, Sorensen RU.
    Ann Allergy; 1994 May; 72(5):395-403; quiz 403-4, 407. PubMed ID: 8179225
    [Abstract] [Full Text] [Related]

  • 2. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
    Hershfield MS.
    Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
    Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, Perignon JL, Morgan G, Gaspar B, Fairbanks LD, Skeoch CH, Moseley A, Harvey M, Levinsky RJ, Valerio D.
    Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
    [Abstract] [Full Text] [Related]

  • 4. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.
    Hershfield MS.
    Hum Mutat; 1995 Feb; 5(2):107-12. PubMed ID: 7749407
    [Abstract] [Full Text] [Related]

  • 5. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
    Bordignon C, Mavilio F, Ferrari G, Servida P, Ugazio AG, Notarangelo LD, Gilboa E, Rossini S, O'Reilly RJ, Smith CA.
    Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
    [Abstract] [Full Text] [Related]

  • 6. Cost analysis of treatments for severe combined immunodeficiency patients caused by adenosine deaminase deficiency: comparison of gene therapy and bone marrow transplantation.
    Imai H.
    Hokkaido Igaku Zasshi; 1998 Mar; 73(2):137-45. PubMed ID: 9612707
    [Abstract] [Full Text] [Related]

  • 7. Adenosine deaminase deficiency.
    Hirschhorn R.
    Immunodefic Rev; 1990 Mar; 2(3):175-98. PubMed ID: 2078332
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J, Zhang F, Giannakopoulos A, Adams S, Fairbanks LD, Gaspar J, Henderson L, Xu-Bayford JH, Davies EG, Veys PA, Kinnon C, Thrasher AJ.
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
    Chun JD, Lee N, Kobayashi RH, Chaffee S, Hershfield MS, Stiehm ER.
    Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
    [Abstract] [Full Text] [Related]

  • 13. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency.
    Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB.
    J Pediatr; 2001 Jul; 139(1):44-50. PubMed ID: 11445793
    [Abstract] [Full Text] [Related]

  • 14. Bone marrow transplantation in congenital immunodeficiency diseases.
    Porta F, Friedrich W.
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S21-3. PubMed ID: 9630319
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
    Girault D, Le Deist F, Debré M, Pérignon JL, Herbelin C, Griscelli C, Sciudery D, Hershfield M, Fischer A.
    Arch Fr Pediatr; 1992 Apr; 49(4):339-43. PubMed ID: 1497422
    [Abstract] [Full Text] [Related]

  • 16. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency.
    Bax BE, Bain MD, Fairbanks LD, Webster AD, Ind PW, Hershfield MS, Chalmers RA.
    Eur J Haematol; 2007 Oct; 79(4):338-48. PubMed ID: 17680812
    [Abstract] [Full Text] [Related]

  • 17. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.
    Hershfield MS.
    Clin Immunol Immunopathol; 1995 Sep; 76(3 Pt 2):S228-32. PubMed ID: 7554473
    [Abstract] [Full Text] [Related]

  • 18. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
    Blaese RM.
    Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
    [Abstract] [Full Text] [Related]

  • 19. Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.
    Kanegane H, Taneichi H, Nomura K, Wada T, Yachie A, Imai K, Ariga T, Santisteban I, Hershfield MS, Miyawaki T.
    Pediatr Transplant; 2013 Feb; 17(1):E29-32. PubMed ID: 22805442
    [Abstract] [Full Text] [Related]

  • 20. [Gene therapy for adenosine deaminase deficiency].
    Sakiyama Y, Ariga T, Ohtsu M.
    Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.